Neurocrine Biosciences, Inc.
US ˙ NasdaqGS ˙ US64125C1099

SecurityNBIX / Neurocrine Biosciences, Inc.
InstitutionRYDEX VARIABLE TRUST - Biotechnology Fund Variable Annuity
Latest Disclosed Ownership1,195 shares
Latest Disclosed Value $ 150,199
RYDEX VARIABLE TRUST - Biotechnology Fund Variable Annuity reports 9.26% decrease in ownership of NBIX / Neurocrine Biosciences, Inc.

On August 27, 2025 - RYDEX VARIABLE TRUST - Biotechnology Fund Variable Annuity filed a NPORT-P form disclosing ownership of 1,195 shares of Neurocrine Biosciences, Inc. (US:NBIX) valued at $150,200 USD as of June 30, 2025. The entity filed a previous NPORT-P on May 29, 2025 disclosing 1,317 shares of Neurocrine Biosciences, Inc.. This represents a change in shares of -9.26% during the quarter. The current value of the position is $199,983 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2025-08-27 2025-06-30 NP Neurocrine Biosciences EC US64125C1099 1,195 -122 -9.26 150 3.45 1.6693
2025-05-29 2025-03-31 NP Neurocrine Biosciences EC US64125C1099 1,317 43 3.38 146 -16.18 1.5474
2025-03-03 2024-12-31 NP Neurocrine Biosciences EC US64125C1099 1,274 -186 -12.74 174 2.98 1.7434
2024-11-29 2024-09-30 NP Neurocrine Biosciences EC US64125C1099 1,460 89 6.49 168 -10.64 1.5237
2024-08-29 2024-06-30 NP Neurocrine Biosciences EC US64125C1099 1,371 -231 -14.42 189 -14.55 1.7207
2024-05-30 2024-03-31 NP Neurocrine Biosciences EC US64125C1099 1,602 13 0.82 221 5.26 1.8738
2024-02-29 2023-12-31 NP Neurocrine Biosciences EC US64125C1099 1,589 -300 -15.88 209 -1.42 1.7160
2023-11-29 2023-09-30 NP Neurocrine Biosciences EC US64125C1099 1,889 -207 -9.88 213 7.61 1.8400
2023-08-28 2023-06-30 NP Neurocrine Biosciences EC US64125C1099 2,096 -18 -0.85 198 -7.51 1.5598
2023-05-30 2023-03-31 NP Neurocrine Biosciences EC US64125C1099 2,114 -275 -11.51 214 -25.26 1.6207
2023-02-28 2022-12-31 NP Neurocrine Biosciences EC US64125C1099 2,389 91 3.96 285 16.80 1.7256
2022-11-29 2022-09-30 NP Neurocrine Biosciences EC US64125C1099 2,298 -107 -4.45 244 4.27 1.7033
2022-08-29 2022-06-30 NP Neurocrine Biosciences EC US64125C1099 2,405 -271 -10.13 234 -6.40 1.6084
2022-05-26 2022-03-31 NP Neurocrine Biosciences EC US64125C1099 2,676 -617 -18.74 251 -10.71 1.4824
2022-02-28 2021-12-31 NP Neurocrine Biosciences EC US64125C1099 3,293 383 13.16 280 0.36 1.2393
2021-11-29 2021-09-30 NP Neurocrine Biosciences EC US64125C1099 2,910 -31 -1.05 279 -2.45 1.1733
2021-08-27 2021-06-30 NP Neurocrine Biosciences EC US64125C1099 2,941 -230 -7.25 286 -7.14 1.1988
2021-05-27 2021-03-31 NP Neurocrine Biosciences EC US64125C1099 3,171 -289 -8.35 308 -6.95 1.3876
2021-03-01 2020-12-31 NP Neurocrine Biosciences EC US64125C1099 3,460 -642 -15.65 332 -15.99 1.3506
2020-11-25 2020-09-30 NP Neurocrine Biosciences EC US64125C1099 4,102 325 8.60 394 -14.35 1.6463
2020-08-27 2020-06-30 NP Neurocrine Biosciences EC US64125C1099 3,777 -40 -1.05 461 39.39 1.8570
2020-06-01 2020-03-31 NP Neurocrine Biosciences EC US64125C1099 3,817 -244 -6.01 330 -24.31 2.0221
2020-03-02 2019-12-31 NP Neurocrine Biosciences EC US64125C1099 4,061 201 5.21 437 25.65 2.0205
2019-11-27 2019-09-30 NP Neurocrine Biosciences EC US64125C1099 3,860 3,860 348 1.8452
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.